Rajiv Dua, MD
Family Medicine · Columbia, MDNPI 1043326945
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,698 of the $6,871 with a category attached, or 68.4%. 42 manufacturers reported payments, led by Merck at 44.1% of the total. 2025 is the largest year on record at $2,119, 4.2 times the $499 reported in 2019. Among family medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Novo Nordisk$819
- AbbVie$414
- Amarin Pharma, Inc.$289
- Lilly USA, LLC$261
- Abbott$196
- plus $2K from 36 others
Across 140 payments — averaging $5526.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$352K
- Genentech, Inc.$175K
- Eli Lilly$68K
- F. Hoffmann-la Roche AG$68K
- Seqirus USA Inc$33K
- GSK$29K
- plus $49K from 5 others
What the payments were for
- Travel & lodging$2,16131%
- Food & beverage$4,69868%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,871 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $94,672 |
| EliquisApixaban | 52 | $61,547 |
| JardianceEmpagliflozin | 23 | $30,947 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $21,109 |
| FarxigaDapagliflozin Propanediol | 14 | $20,435 |
| XareltoRivaroxaban | 15 | $19,405 |
| MounjaroTirzepatide | 17 | $18,211 |
| Levemir FlexpenInsulin Detemir | 11 | $6,225 |
| GemtesaVibegron | 11 | $5,629 |
| Atorvastatin Calcium | 298 | $4,331 |
| Rosuvastatin Calcium | 132 | $2,347 |
| Amlodipine Besylate | 219 | $1,858 |
| SynthroidLevothyroxine Sodium | 28 | $1,834 |
| Metoprolol Succinate | 100 | $1,775 |
| Tamsulosin Hcl | 95 | $1,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $819 | $94,67276 claims |
| PfizerEliquis | $131 | $61,54752 claims |
| Boehringer IngelheimJardiance | $110 | $30,94723 claims |
| AstraZenecaFarxiga | $143 | $20,43514 claims |
| Johnson & JohnsonXarelto | $79 | $19,40515 claims |
| Lilly USA, LLCMounjaro | $261 | $18,21117 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $73 | $5,62911 claims |
| AbbVieSynthroid | $414 | $1,83428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Columbia
- Alkesh PatelColumbia$42K
- Njideka UdochiColumbia$12K
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
- Cynthia KleppingerSilver Spring$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.